{"id":29369,"date":"2014-02-15T17:14:49","date_gmt":"2014-02-15T16:14:49","guid":{"rendered":"http:\/\/www.diabsite.de\/diabetes-weblog\/?p=29369"},"modified":"2014-03-04T21:10:35","modified_gmt":"2014-03-04T20:10:35","slug":"herzinsuffizienzrisiko-unter-saxagliptin","status":"publish","type":"post","link":"https:\/\/www.diabsite.de\/diabetes-weblog\/2014\/02\/15\/herzinsuffizienzrisiko-unter-saxagliptin\/","title":{"rendered":"Herzinsuffizienzrisiko unter Saxagliptin"},"content":{"rendered":"<p>Am 11. Februar 2014 teilte die FDA (Amerikanische Arzneibeh\u00f6rde) mit, dass sie von Bristol-Myers Squibb\/AstraZeneca, den Herstellern des Diabetesmedikaments Saxagliptin (Onglyza&reg;, Komboglyze&reg;), einem Dipeptidyl-Peptidase&nbsp;(DPP)-4-Hemmer, die klinischen Daten angefordert habe, um das Herzinsuffizienz-Risiko unter Saxagliptin zu \u00fcberpr\u00fcfen. <a href=\"https:\/\/www.diabsite.de\/aktuelles\/nachrichten\/2014\/140215.html\" target=\"_blank\" class=\"ds\" title=\"zur Nachricht (neues Fenster)\">Nachricht lesen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Am 11. Februar 2014 teilte die FDA (Amerikanische Arzneibeh\u00f6rde) mit, dass sie von Bristol-Myers Squibb\/AstraZeneca, den Herstellern des Diabetesmedikaments Saxagliptin (Onglyza&reg;, Komboglyze&reg;), einem Dipeptidyl-Peptidase&nbsp;(DPP)-4-Hemmer, die klinischen Daten angefordert habe, um das Herzinsuffizienz-Risiko unter Saxagliptin zu \u00fcberpr\u00fcfen. Nachricht lesen<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[3340,3339,3338],"_links":{"self":[{"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/posts\/29369"}],"collection":[{"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/comments?post=29369"}],"version-history":[{"count":4,"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/posts\/29369\/revisions"}],"predecessor-version":[{"id":29387,"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/posts\/29369\/revisions\/29387"}],"wp:attachment":[{"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/media?parent=29369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/categories?post=29369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.diabsite.de\/diabetes-weblog\/wp-json\/wp\/v2\/tags?post=29369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}